Skip to Main Content

Francine Foss, MD

Professor of Medicine (Hematology) and of Dermatology

Extensive Research Description

Over the last 10 years I have been a leader in the establishment of an international T cell lymphoma working group. I initiated a T Cell Lymphoma workshop at the International Conference on Malignant Lymphoma 12 years ago and from that workshop, the United States Peripheral T cell Lymphoma group was formed. I subsequently initiated the first T Cell Lymphoma Forum, an international meeting incorporating basic and clinical sciences related to T cell lymphomas. My Co-Chairs for the meeting are Dr Kensei Tobinai from Tokyo and more recently also by Dr. Owen O’Connor from Columbia University. This year was the 8th annual meeting ( This meeting is now recognized as the pre-eminent international T cell Lymphoma meeting. A number of collaborations have arisen from these meetings and there is now a world-wide effort to coordinate the care of patients with T cell lymphomas.

Another initiative that I undertook was to establish a T Cell Lymphoma Registry. I initiated and am the Principal Investigator for the COMPLETE T cell Registry (www. Clinical REGISTRY). This is a US based registry to determine the frequency of types of T cell lymphoma, physician’s treatment patterns, outcomes with therapy, and prognostic factors associated with common and rare subtypes. Thus far this registry has enrolled 500 patients in its first phase, and the second phase of enrollment is about to begin. I have also been a co-Founder of a European based registry, the TCELL PROJECT ( This registry is similar to COMPLETE but includes pathologic review and includes many other countries in Asia, South America, and Europe as well as in the US. This registry has enrolled 1000 patients and is ongoing. In a recent initiative, I have collaborated with several countries in Latin American to initiate their own registry which will interface with our existing registries.

I was one of the founders of the United States Cutaneous Lymphoma Consortium. This organization includes oncologists, dermatologists, radiation oncologists, and pathologists and its goal is to develop novel clinical trials and to define clinical approaches for patients with cutaneous lymphomas. I also serve as a Co-Chair of the Registry Committee and have been instrumental in starting a patient registry for both T and B cell cutaneous lymphoma patients. This registry has a research focus. I am now the President of the USCLC.

Research Interests

Biological Factors; Graft vs Host Disease; Hodgkin Disease; Immune System Diseases; Leukemia, Hairy Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Sezary Syndrome; Skin Neoplasms; Leukemia, B-Cell; Leukemia, T-Cell; Leukemia, Prolymphocytic, T-Cell; Leukemia, Prolymphocytic, B-Cell; Composite Lymphoma; Chemicals and Drugs

Public Health Interests


Clinical Trials

ConditionsStudy Title
Non-Hodgkin's LymphomaA Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin's LymphomaA Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Non-Hodgkin's LymphomaA Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Multiple MyelomaA Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Hodgkin's LymphomaA Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
KidneyA Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Phase IA Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Non-Hodgkin's LymphomaA Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Hodgkin's LymphomaA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Lymphoid LeukemiaA Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Non-Hodgkin's LymphomaA Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Lymphoid LeukemiaA Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Non-Hodgkin's LymphomaA Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Non-Hodgkin's LymphomaAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Hodgkin's Lymphoma; Lymphoid LeukemiaA Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Non-Hodgkin's LymphomaA Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Leukemia, not otherwise specified; Leukemia, other; Myeloid and Monocytic LeukemiaA Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Lymphoid Leukemia; Non-Hodgkin's Lymphoma; Phase IAn Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia